Can lurasidone cause elevated hepatic transaminases?

Can Lurasidone Cause Elevated Liver Enzymes?

Lurasidone does not typically cause clinically significant elevations in liver transaminases, and hepatotoxicity is not listed as a recognized adverse effect in the FDA prescribing information. 1

Evidence from FDA Labeling

The FDA prescribing information for lurasidone does not include warnings about hepatotoxicity or liver enzyme elevations in its Warnings and Precautions section. 1 The label discusses multiple safety concerns including:

• Increased mortality in elderly patients with dementia-related psychosis 1
• Neuroleptic malignant syndrome 1
• Tardive dyskinesia 1
• Metabolic changes (hyperglycemia, dyslipidemia, weight gain) 1

Notably absent from this comprehensive safety profile is any mention of hepatotoxicity or transaminase elevation as a recognized adverse effect. 1

Dosing Adjustments in Hepatic Impairment

The FDA label does recommend dose reduction in patients with pre-existing moderate to severe hepatic impairment (Child-Pugh score ≥7), stating that these patients have higher lurasidone exposure. 1 However, this recommendation reflects concerns about drug clearance in compromised livers rather than evidence that lurasidone causes liver injury. 1

Clinical Trial and Real-World Evidence

Metabolic Safety Profile

Lurasidone is characterized by minimal metabolic side effects, particularly regarding weight gain, glucose, and lipid alterations. 2 The drug's favorable metabolic profile extends to hepatic safety—there is no evidence from clinical trials of clinically meaningful liver enzyme elevations. 3, 2

Pharmacokinetic Studies

Research examining lurasidone's effects on cytochrome P450 enzymes demonstrates that chronic treatment influences CYP enzyme expression in the liver, but these changes represent metabolic adaptation rather than hepatotoxicity. 4, 5 Lurasidone is primarily metabolized by CYP3A4 and does not significantly inhibit or induce CYP450 enzymes. 6

Therapeutic Drug Monitoring Data

A 2024 study of 120 Chinese patients receiving lurasidone found no reports of hepatotoxicity or liver enzyme elevations despite comprehensive monitoring. 7 The study focused on dose optimization and drug interactions, not hepatic safety concerns, suggesting liver toxicity is not a clinical issue requiring surveillance. 7

Comparison to Hepatotoxic Medications

When evaluating medications for hepatotoxicity risk, lurasidone does not appear on lists of drugs requiring liver enzyme monitoring. 8 In contrast, medications with established hepatotoxicity (such as lomitapide, tolvaptan, and certain statins) carry black box warnings and mandate regular transaminase monitoring. 9

Clinical Implications

If a patient on lurasidone develops elevated liver enzymes, the clinician should:

• Investigate alternative causes including non-alcoholic fatty liver disease, alcohol use, viral hepatitis, and concomitant hepatotoxic medications 10
• Review all medications using resources like the LiverTox® database to identify other potential hepatotoxins 10
• Obtain a complete liver panel (ALT, AST, alkaline phosphatase, bilirubin, albumin, INR) and viral hepatitis serologies 10
• Consider abdominal ultrasound as first-line imaging (84.8% sensitivity, 93.6% specificity for hepatic steatosis) 10
• Calculate the FIB-4 score to assess for advanced fibrosis risk 10

Lurasidone discontinuation is not indicated solely for mild transaminase elevation, as the drug is not recognized as hepatotoxic. 1, 3

Common Pitfalls

• Do not attribute elevated liver enzymes to lurasidone without excluding more common causes such as metabolic syndrome, alcohol use, viral hepatitis, or other medications 10
• Do not discontinue lurasidone based on mild ALT elevation (<3× upper limit of normal) without investigating alternative etiologies 10
• Do not confuse dose adjustment recommendations in pre-existing liver disease with evidence of drug-induced hepatotoxicity—these are distinct safety considerations 1